Slingshot members are tracking this corporate initiative:
Incyte acquires the European operation of ARIAD Pharmaceuticals for $140M upfront plus milestones and tiered royalties
Do you think this event is important to the companies below? How will it affect their stock price?
The planned acquisition of a fully-integrated and established pan-European team of 125 employees, including medical, sales and marketing personnel, will further Incyte’s strategic plan and accelerate the establishment of its operations in Europe, helping to optimize clinical development and maximize the potential of future European launches for Incyte’s portfolio of products in development.
Under the terms of the license agreement, Incyte will receive an exclusive license to develop and commercialize Iclusig, the only approved BCR-ABL inhibitor with activity against the T315I mutation, throughout Europe and in other select countries. Iclusig is approved in Europe for the treatment of patients with chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of certain second generation BCR-ABL inhibitors and all patients who have the T315I mutation.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: May 09, 2016 Projected Implementation: Q2, 2016 Relevance Tracked Until: Q3, 2016
Don’t see a project related to the strategic initiative you care about?
Related Keywords License Agreement, European Operations, Acquisition, Iclusig, Chronic Myeloid Leukemia, Cml, Acute Lymphoblastic Leukemia, T315i Mutation